- Home
- EM vs GLSI Comparison
EM vs GLSI Comparison
Compare EM & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EM
- GLSI
- Stock Information
- Founded
- EM 2017
- GLSI 2006
- Country
- EM China
- GLSI United States
- Employees
- EM N/A
- GLSI 6
- Industry
- EM Other Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- EM Consumer Discretionary
- GLSI Health Care
- Exchange
- EM Nasdaq
- GLSI Nasdaq
- Market Cap
- EM 191.0M
- GLSI 159.8M
- IPO Year
- EM 2021
- GLSI 2020
- Fundamental
- Price
- EM $1.10
- GLSI $12.84
- Analyst Decision
- EM Strong Buy
- GLSI Strong Buy
- Analyst Count
- EM 1
- GLSI 1
- Target Price
- EM $1.00
- GLSI $38.00
- AVG Volume (30 Days)
- EM 1.7M
- GLSI 42.7K
- Earning Date
- EM 01-28-2025
- GLSI 11-14-2024
- Dividend Yield
- EM N/A
- GLSI N/A
- EPS Growth
- EM N/A
- GLSI N/A
- EPS
- EM 0.03
- GLSI N/A
- Revenue
- EM $269,745,696.00
- GLSI N/A
- Revenue This Year
- EM N/A
- GLSI N/A
- Revenue Next Year
- EM $6.16
- GLSI N/A
- P/E Ratio
- EM $32.87
- GLSI N/A
- Revenue Growth
- EM N/A
- GLSI N/A
- 52 Week Low
- EM $0.46
- GLSI $8.00
- 52 Week High
- EM $1.18
- GLSI $21.44
- Technical
- Relative Strength Index (RSI)
- EM 82.12
- GLSI 49.18
- Support Level
- EM $0.68
- GLSI $12.03
- Resistance Level
- EM $1.02
- GLSI $13.10
- Average True Range (ATR)
- EM 0.04
- GLSI 0.84
- MACD
- EM 0.02
- GLSI 0.05
- Stochastic Oscillator
- EM 95.00
- GLSI 48.11
About EM Smart Share Global Limited
Smart Share Global Ltd is a consumer tech company providing mobile device charging service through an extensive online and offline network in China. It provides service through power banks, placed in POIs operated by location partners, such as entertainment venues, restaurants, shopping centers, hotels, transportation hubs, and public spaces. Through the mini-programs, users rent the power banks to carry with them when use the service and can return the power banks at any of the POIs, enabled by the expansive network and powerful technologies.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.